4,5-二氨基-6-羟基嘧啶 | 1672-50-0

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4,5-二氨基-6-羟基嘧啶
• 中文别名: 5,6-二氨基-4-嘧啶醇；5,6-二氨基-4(1H)-嘧啶酮；5,6-二氨基-4-羟基嘧啶
• 英文名称: 4,5-diamino-6-hydroxypyrimidine
• 英文别名: 4,5-Diamino-6-hydroxy-pyrimidin；5,6-diaminopyrimidin-4-ol；5,6-diamino-4-hydroxypyrimidine；5,6-Diamino-4-hydroxy-pyrimidin；4-hydroxy-5,6-diaminopyrimidine；4,5-Diaminohypoxanthine；4,5-diamino-1H-pyrimidin-6-one
• CAS: 1672-50-0
• 化学式: C₄H₆N₄O
• mdl: MFCD00006114
• 分子量: 126.118
• InChiKey: PWRHKLKFADDKHS-UHFFFAOYSA-N

物化性质

• 熔点：
  239 °C
• 沸点：
  221.5±50.0 °C(Predicted)
• 密度：
  1.84
• 闪点：
  87.8℃
• 溶解度：
  可溶于水基（轻微）、DMSO（轻微）、水（非常轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.5
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  29335990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放于惰性气体中，避免接触空气。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4,5-Diamino-6-hydroxypyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4,5-Diamino-6-hydroxypyrimidine
CAS number: 1672-50-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H6N4O
Molecular weight: 126.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：该品的硫酸盐（[52502-66-6]）熔点为270℃（分解）。

用途：作为医药中间体，主要用于生产抗肿瘤药物巯嘌呤和溶癌呤。

生产工艺：由2-巯基-4-氨基-6-羟基嘧啶经亚硝化、还原、消除而制得。

反应信息

• 作为反应物：
  描述：

  4,5-二氨基-6-羟基嘧啶 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 4.0h， 以15%的产率得到4,5-二氨基-6-氯嘧啶
  参考文献：
  名称：

  [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
  [FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)

  摘要：

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。

  公开号：

  WO2004013141A1
• 作为产物：
  描述：

  4,5-Diamino-6-hydroxypyrimidine sulphate 在 polymer-supported carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 24.0h， 生成 4,5-二氨基-6-羟基嘧啶
  参考文献：
  名称：

  WO2007/71966

  摘要：

  公开号：

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• Synthesis and Biological Evaluation of New Dipyridylpteridines, Lumazines, and Related Analogues
  作者：Zina A. A. Abbas、Najwa M. J. Abu-Mejdad、Zeenah W. Atwan、Najim A. Al-Masoudi

  DOI：10.1002/jhet.2651

  日期：2017.3

  methanolic ammonia under drastic conditions. Condensation of 2 or 29 with 2‐oxo‐2‐(thiophen‐2‐yl)acetaldehyde oxime (11) gave the 6‐(2‐thienyl)‐pteridine‐4‐one (12) and 5‐chloro‐2‐(2‐thienyl)pyrido[3,4‐b]pyrazine (31), respectively. All compounds were evaluated for their antiviral activity against the replication of HIV‐1 and HIV‐2 in MT‐4. Some of the synthesized compounds were tested against the bacterial

  4,5-二氨基嘧啶2和3与2,2ʹ-联吡啶（4）的缩合分别得到6,7-双（2-吡啶基）蝶啶-2-一类似物5和7。类似地，6,7-双（2-吡啶基）luamzine衍生物13，15，17，和23，从5,6-二氨基-2- thiopyrimidines反应合成13，14，和22与4，分别，而缩合4,5,6-三氨基嘧啶（25）或5,6-二氨基类似物26与4分别提供了4-氨基蝶啶类似物27和28。得到4-硫代类似物的新蝶啶和lumazines的硫杂化6，8，16，和24。用甲醇氨水处理6和8分别得到4-异is呤类似物9和10。用取代的苯甲酰氯将15烷基化，得到18和19，它们环化为噻唑并蝶啶衍生物20和21分别用多磷酸处理。或者，在剧烈条件下，用甲醇氨处理24，制得27。2或29与2-氧代-2-（噻吩-2-基）乙醛肟（11）的缩合得到6-（2-噻吩基）-哌啶-4-基（12）和5-氯-2-（- 2-噻吩基]吡啶并[3
• [EN] QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] COMPOSÉ DE QUINUCLIDINE COMME LIGANDS DU RÉCEPTEUR NICOTINIQUE ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011053292A1

  公开（公告）日：2011-05-05

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱7受体的配体，可能对治疗中枢神经系统的各种紊乱，特别是情感和神经退行性疾病有用。
• QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Cook, II James H.

  公开号：US20090270405A1

  公开（公告）日：2009-10-29

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱性α7受体的配体，可能对治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病，有用。
• Pyrimidines. Part XXIII. Synthesis of pyrimido[4,5-b][1,4]oxazines by reaction of 4,5-diaminopyrimidine derivatives with α-halogeno-ketones
  作者：Jean Mirza、Wolfgang Pfleiderer、A. D. Brewer、Alexander Stuart、H. C. S. Wood

  DOI：10.1039/j39700000437

  日期：——

  ketone is shown to give pyrimido [4,5-b][1,4]oxazines and not the expected dihydropteridine derivatives. Similar condensations with a number of different α-halogeno-aldehydes and α-halogeno-ketones have been studied, and the factors which control the nature of the product have been determined. Some preliminary studies of the chemical reactivity of pyrimido-[4,5-b][1,4]oxazines have been carried out.

  某些4,5-二氨基嘧啶衍生物与α-溴异丙基甲基酮的缩合反应显示出嘧啶[4,5- b ] [1,4]恶嗪，而不是预期的二氢蝶啶衍生物。已经研究了与许多不同的α-卤代醛和α-卤代酮的类似缩合反应，并确定了控制产物性质的因素。已对嘧啶基-[4,5- b ] [1,4]恶嗪的化学反应性进行了一些初步研究。

表征谱图